The potential role of ER beta isoforms in the clinical management of breast cancer

C A Green, M B Peter, V Speirs, A M Shaaban

Research output: Contribution to journalReview articlepeer-review

20 Citations (Scopus)


The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.

Original languageEnglish
Pages (from-to)374-80
Number of pages7
Issue number4
Publication statusPublished - Oct 2008


  • Animals
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Estrogen Receptor beta
  • Female
  • Humans
  • Models, Genetic
  • Protein Isoforms
  • Structure-Activity Relationship
  • Treatment Outcome
  • Journal Article
  • Review


Dive into the research topics of 'The potential role of ER beta isoforms in the clinical management of breast cancer'. Together they form a unique fingerprint.

Cite this